Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01PBW
|
|||
| Former ID |
DIB015191
|
|||
| Drug Name |
CB-839
|
|||
| Indication | Breast cancer [ICD-11: 2C60-2C65] | Phase 2 | [1] | |
| Renal cell carcinoma [ICD-11: 2C90; ICD-10: C64; ICD-9: 189] | Phase 2 | [1] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1] | ||
| leukaemia [ICD-11: 2A60-2B33; ICD-9: 208.9] | Phase 1 | [2] | ||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H24F3N7O3S
|
|||
| Canonical SMILES |
C1=CC=NC(=C1)CC(=O)NC2=NN=C(S2)CCCCC3=NN=C(C=C3)NC(=O)CC4=CC(=CC=C4)OC(F)(F)F
|
|||
| InChI |
1S/C26H24F3N7O3S/c27-26(28,29)39-20-9-5-6-17(14-20)15-22(37)31-21-12-11-18(33-34-21)7-1-2-10-24-35-36-25(40-24)32-23(38)16-19-8-3-4-13-30-19/h3-6,8-9,11-14H,1-2,7,10,15-16H2,(H,31,34,37)(H,32,36,38)
|
|||
| InChIKey |
PRAAPINBUWJLGA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1439399-58-2
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Glutaminase (GLS) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | ClinicalTrials.gov (NCT02071862) Study of the Glutaminase Inhibitor CB-839 in Solid Tumors. U.S. National Institutes of Health. | |||
| REF 3 | Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. Mol Cancer Ther. 2014 Apr;13(4):890-901. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.